Acquisition by Pepose Jay of 48000 shares of Ocuphire Pharma at 1.79 subject to Rule 16b-3

OCUPDelisted Stock  USD 1.13  0.06  5.04%   
Slightly above 62% of Ocuphire Pharma's investor base is looking to short. The analysis of current outlook of investing in Ocuphire Pharma suggests that many traders are alarmed regarding Ocuphire Pharma's prospects. Ocuphire Pharma's investing sentiment overview a quick insight into current market opportunities from investing in Ocuphire Pharma. Many technical investors use Ocuphire Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Ocuphire Pharma Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at globenewswire.com
Macroaxis News: globenewswire.com
  

Ocuphire Pharma Fundamental Analysis

We analyze Ocuphire Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocuphire Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocuphire Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Ratio

Current Ratio Comparative Analysis

Ocuphire Pharma is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Ocuphire Pharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ocuphire Pharma stock to make a market-neutral strategy. Peer analysis of Ocuphire Pharma could also be used in its relative valuation, which is a method of valuing Ocuphire Pharma by comparing valuation metrics with similar companies.

Peers

Ocuphire Pharma Related Equities

FBIOFortress Biotech   16.39   
0%
100.0%
FBIOPFortress Biotech   13.65   
0%
83.0%
RVPHReviva Pharmaceuticals   8.77   
0%
53.0%
MBIOMustang Bio   5.26   
0%
32.0%
RNAZTranscode Therapeutics   2.94   
0%
17.0%
CKPTCheckpoint Therapeutics   2.57   
0%
15.0%
KODKodiak Sciences   1.83   
0%
11.0%
PLXProtalix Biotherapeutics   1.78   
0%
10.0%
RIGLRigel Pharmaceuticals   0.97   
5.0%
0%
EYPTEyepoint Pharmaceuticals   2.21   
13.0%
0%
CGTXCognition Therapeutics   2.44   
14.0%
0%
SLSSellas Life   3.42   
20.0%
0%
RVPHWReviva Pharmaceuticals   4.35   
26.0%
0%
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Consideration for investing in Ocuphire Stock

If you are still planning to invest in Ocuphire Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ocuphire Pharma's history and understand the potential risks before investing.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Equity Valuation
Check real value of public entities based on technical and fundamental data
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine